In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosis
Aristides D. Tagalakis(Edge Hill University), Cynthia Yu‐Wai‐Man(University College London), Shivam Madaan(The London College), Scott D. Larsen(University of Michigan), Saurabh Goyal(Queen Mary's Hospital Sidcup), Ian Rodrigues(St Thomas' Hospital), Peng T. Khaw(National Institute for Health Research), Kin Sheng Lim(St Thomas' Hospital), Richard R. Neubig(Michigan State University)
Cited by 40
Related Papers
Genome-wide analyses identify 68 new loci associated with intraocular pressure and improve risk prediction for primary open-angle glaucoma
|Nature Genetics|2018|384
Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up
|Ophthalmology|2018|320
Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 3 Years of Follow-up
|Ophthalmology|2019|252
A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract
|Ophthalmology|2018|222
Mechanism of Action of Bimatoprost, Latanoprost, and Travoprost in Healthy Subjects
|Ophthalmology|2008|167